Clinical trials: Early Parkinson Disease, open to volunteers
Parkinson's Disease (PD), Early Onset Parkinson Disease
AAV2-hAADC for Parkinson's Disease (PDCS-01)
This study is looking at whether a gene therapy called AAV2-hAADC is safe and may help people with Parkinson's Disease. AAV2-hAADC is intended to increase the levels of dopamine in your brain.
- Trial name
- PDCS-01 (NCT07267065)
- Testing
- AAV2-hAADC
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Russell Lonser
Parkinson's Disease
Study to Assess Real Life Effectiveness of Foslevodopa/Foscarbidopa in Adult German Participants at Initial Stages of Advanced Parkinson's Disease (EARLY-FOS)
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person.
- Trial name
- NCT06916507
- Where
- 19 sites in Germany
- Volunteers
- 125 people
- Sponsor
- AbbVie
Parkinson Disease, Progressive Supranuclear Palsy
Early Biomarkers of Neurodegeneration in Parkinsonian Syndromes
Parkinson's disease (PD) is the most common degenerative Parkinson's syndrome and is linked, among other things, to the excessive accumulation of an abnormally aggregating protein, alpha-synuclein.
- Trial name
- SODIPARK (NCT06155942)
- Testing
- 7 Tesla MRI
- Where
- 6 sites in France
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
Parkinson Disease (PD), Gut Microbiota
Developing Precision Microbiota-Based Cocktail Modification Therapy to Delay the Progression of Parkinson's Disease (PD) - Use Preclinical Human Trials to Confirm the Impact of the Optimal "Probiotic Y7, Tryptophan and Branched-chain Amino Acid" Cocktail Formula on Early Stage PD Patients
Preclinical human trials will be utilized to validate the research direction, followed by clinical trials to assess the impact of a cocktail formula product containing the optimal probiotic Y7 combined metabolites on motor…
- Conditions
- Parkinson Disease (PD), Gut Microbiota, Probiotic
- Trial name
- NCT07619560
- Testing
- Y7
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- Taipei Medical University
Parkinson Disease, Amyotrophic Lateral Sclerosis (ALS)
Discovery and Validation of Protein Structural Complexes in Circulating Biofluids As Novel Biomarkers for Early Diagnosis, Prognosis and Therapeutic Management of Patients Affected by Neurodegenerative Disorders
Neurodegenerative disorders (NDDs), such as Parkinson¿s disease (PD), Alzheimer¿s disease (AD), Frontotemporal dementia (FTD) and Amyotrophic Lateral Sclerosis (ALS) are characterized by aggregation and intracellular accumulation…
- Conditions
- Parkinson Disease, Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Alzheimer's Disease (AD)
- Trial name
- NCT06803784
- Testing
- Genetic: whole genome sequencing, whole exome sequencing
- Where
- Italy
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Neuromed IRCCS
Parkinson Disease
Efficacy, Safety, Tolerability, and Biomarker Effects of GT-02287 in Early Parkinson's Disease
The purpose of this study is to assess the efficacy, the safety, and the effect on biomarkers of 2 dose levels of oral GT-02287 over placebo after 48 weeks of treatment in treated and untreated participants with early PD.
- Trial name
- NCT07280299
- Testing
- Low Dose GT-02287, High Dose GT-02287
- Volunteers
- 111 people
- Sponsor
- Gain Therapeutics, Inc.
Parkinson Disease
Earlier Diagnosis and Better Treatment Mission Related to the Cohort Programme
The Luxembourg Parkinson's Study is an ongoing longitudinal nationwide monocentric observational study. It collects extensive clinical, molecular, genetic, and digital device-based longitudinal data, as well as foreseen…
- Trial name
- LuxPARK (NCT05266872)
- Testing
- Observational study with sample and data collection
- Where
- 2 sites in Luxembourg
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Luxembourg Institute of Health
Parkinson's Disease (PD)
A Phase 2 Study to Assess the Effects of SUL-238 on High Energy Phosphates With ³¹P-MRS in Patients With Early, Untreated Parkinson's Disease
The main goal of the study is to investigate how well the new drug SUL-238 works in Parkinson's Disease (PD). This is done by means of an MRS scan. An MRS scan is similar to a regular MRI scan.
- Trial name
- SHEPHERD (NCT07322887)
- Testing
- SUL-238 (1500 mg t.i.d.) film-coated tablets, SUL-238 (500 mg t.i.d.) film-coated tablets
- Where
- Netherlands
- Volunteers
- 45 people
- Sponsor
- GEN İlaç ve Sağlık Ürünleri A.Ş.
Dementia, Alzheimer Disease
The Swedish BioFINDER 2 Study
The Swedish BioFINDER 2 study is a new study that will launch in 2017 and extends the previous cohorts of BioFINDER 1 study (www.biofinder.se). BioFINDER 1 is used e.g.
- Conditions
- Dementia, Alzheimer Disease, Parkinson Disease, Lewy Body Disease
- Trial name
- BioFINDER2 (NCT03174938)
- Testing
- Flutemetamol F18 Injection, [18F]-RO6958948, Elecsys (Roche) Abeta42, Ttau and Ptau
- Where
- 2 sites in Sweden
- Volunteers
- 2,950 people, healthy volunteers welcome
- Sponsor
- Skane University Hospital
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes
This prospective observational study aims to identify and preliminarily validate molecular biomarkers, including microRNAs and metabolites, for the early differentiation of Parkinson's disease (PD) from atypical parkinsonian…
- Conditions
- PARKINSON DISEASE (Disorder), Atypical Parkinsonism, Multiple System Atrophy, Progressive Supranuclear Palsy (PSP)
- Trial name
- BIOMARK-PS (NCT07604883)
- Where
- 2 sites in Poland
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- International Institute of Molecular and Cell Biology in Warsaw
Parkinson Disease
AV133 Longitudinal Imaging Study in Patients With Early and Prdromal Parkinson's Disease
A total of 38 patients with early-stage Parkinson's disease and 38 patients with prodromal Parkinson's disease are planned to be enrolled in this study and examined for longitudinal changes in [18F]AV-133 through follow-up…
- Trial name
- NCT06456684
- Testing
- Fluoro[18F]promethazine
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Xuanwu Hospital, Beijing
Parkinson's Disease
Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person.
- Trial name
- P25-758 PUCCIN (NCT07227896)
- Where
- 10 sites in United States, Israel and 2 more
- Volunteers
- 100 people
- Sponsor
- AbbVie
Parkinson Disease
Chinese EOPD Registry
The purpose of the Chinese Early-onst Parkinson's disease Registry (CEOPDR) is to develop a database of persons with early-onset Parkinson's disease (EOPD) in China.
- Trial name
- NCT03508960
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Xiangya Hospital of Central South University
Parkinson Disease (PD)
VG081821AC Tablets for Early to Mid-stage Parkinson's Disease
This study is testing a new oral medication called VG081821AC to see if it can help improve movement symptoms in people with early to mid-stage Parkinson's disease.
- Trial name
- NCT07725562
- Testing
- VG081821AC
- Where
- China
- Volunteers
- 152 people
- Sponsor
- Zhejiang Vimgreen Pharmaceuticals, Ltd.
Parkinson's Disease (PD), Mild to Moderate Parkinson's Disease
A Phase I Study in Healthy Volunteers and Parkinson's Disease (PD) Patients.
The goal of this trial is to learn if MTX325 can be developed as a potential disease-modifying treatment for Parkinson's Disease. Parts 1-4 complete, Part 5 (multiple doses in patients with Parkinson's Disease) in progress.
- Conditions
- Parkinson's Disease (PD), Mild to Moderate Parkinson's Disease, Early Stage Parkinson's Disease
- Trial name
- NCT07630545
- Testing
- MTX325
- Where
- 18 sites in Australia, France and 2 more
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Mission Therapeutics
Parkinson´s Disease, REM Sleep Behavior Disorder (iRBD)
The Swedish BioFINDER Sleep Study
BioFINDER-Sleep study was established in 2021 and will include patients with early Parkinson´s disease (PD) and persons with iRBD to provide essential insights into the underlying mechanisms of the progressive neurodegenerative…
- Conditions
- Parkinson´s Disease, REM Sleep Behavior Disorder (iRBD), Lewy Body Disease, Synucleinopathy
- Trial name
- NCT07533799
- Testing
- Dopamine transporter PET scan with [18F]FE-PE2I, Magnetic resonance imaging (MRI), [123I] MIBG scintigraphy of the heart
- Where
- Sweden
- Volunteers
- 650 people, healthy volunteers welcome
- Sponsor
- Skane University Hospital
Mild Cognitive Impairment (MCI), Subjective Cognitive Complaints (SCCs)
EARLY-COGN^3 - Smart Digital Solutions for EARLY Treatment of COGnitive Disability: a Neuropsychological, Neurophysiological and Neurobiological Perspective in Chronic Neurological Diseases - PNRR-MCNT2-2023-12377069
The increase in life expectancy in recent decades has led to a large number of people living into old age and an increased risk of developing Chronic Neurological Diseases (CNDs) such as neurodegenerative diseases.
- Conditions
- Mild Cognitive Impairment (MCI), Subjective Cognitive Complaints (SCCs), Parkinson Disease
- Trial name
- EARLY-COGN^3 (NCT06657274)
- Testing
- RICORDO-DTx, Home-based unstructured cognitive stimulation
- Where
- 3 sites in Italy
- Volunteers
- 60 people
- Sponsor
- IRCCS Centro San Giovanni di Dio Fatebenefratelli
Mild Cognitive Impairment (MCI) Amnestic, Parkinson Disease (PD)
Early Stage of Alzheimer's and Parkinson's Diseases, HearIng Relevance (SAPHIR)
The study aims to phenotype hearing in patients with early stage of neurodegenerative disorders to explore the prevalence of various hearing disorders in comparison to a control population.
- Conditions
- Mild Cognitive Impairment (MCI) Amnestic, Parkinson Disease (PD), Healthy Participants
- Trial name
- SAPHIR (NCT07083089)
- Testing
- Thorough Hearing assessment
- Where
- 4 sites in France
- Volunteers
- 309 people, healthy volunteers welcome
- Sponsor
- Cilcare SAS
Parkinson's Disease (PD)
Parkinson's Research In Metagenomic Early Stage Biomarkers
This 2x2 factorial, randomized, controlled pilot study aims to identify a specific microbiota pattern, which could constitute a biomarker of Parkinson's disease, and to evaluate whether specific pathotypes can be associated with…
- Trial name
- PRIME_2025 (NCT07097103)
- Testing
- Mediterranean Diet Intervention, Intensive Physical Activity Intervention, Control
- Where
- 2 sites in Italy
- Volunteers
- 80 people
- Sponsor
- IRCCS San Raffaele Roma
ALS, Amyotrophic Lateral Sclerosis
NYSCF Scientific Discovery Biobank
The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells…
- Conditions
- ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset
- Trial name
- NCT06203106
- Testing
- Biological Sample Collection
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- New York Stem Cell Foundation Research Institute